Deadline Alert: Unicycive Therapeutics, Inc. Investors Have Until November 2, 2026 to Seek Lead Plaintiff Role in Securities Fraud Class Action, Glancy Prongay Wolke & Rotter LLP Reminds Investors

Impact · against what's priced in

The deadline for lead plaintiff applications in the securities fraud class action against Unicycive Therapeutics is a minor administrative update. The underlying litigation and allegations of undisclosed material adverse facts are already factored into the stock's valuation.

UTHR−0.10

No priced-in read yet